CN104169277B - 极光激酶和flt3激酶调节剂 - Google Patents

极光激酶和flt3激酶调节剂 Download PDF

Info

Publication number
CN104169277B
CN104169277B CN201380013544.5A CN201380013544A CN104169277B CN 104169277 B CN104169277 B CN 104169277B CN 201380013544 A CN201380013544 A CN 201380013544A CN 104169277 B CN104169277 B CN 104169277B
Authority
CN
China
Prior art keywords
compound
hydrogen
kinase
aurora
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380013544.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104169277A (zh
Inventor
J·C·瑞德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sareum Ltd
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of CN104169277A publication Critical patent/CN104169277A/zh
Application granted granted Critical
Publication of CN104169277B publication Critical patent/CN104169277B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380013544.5A 2012-02-06 2013-02-04 极光激酶和flt3激酶调节剂 Expired - Fee Related CN104169277B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1202027.7 2012-02-06
GBGB1202027.7A GB201202027D0 (en) 2012-02-06 2012-02-06 Pharmaceutical compounds
PCT/EP2013/052182 WO2013117522A1 (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators

Publications (2)

Publication Number Publication Date
CN104169277A CN104169277A (zh) 2014-11-26
CN104169277B true CN104169277B (zh) 2016-10-12

Family

ID=45896692

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380013544.5A Expired - Fee Related CN104169277B (zh) 2012-02-06 2013-02-04 极光激酶和flt3激酶调节剂

Country Status (18)

Country Link
US (1) US9133180B2 (enExample)
EP (1) EP2812328B1 (enExample)
JP (1) JP6034880B2 (enExample)
KR (1) KR102052780B1 (enExample)
CN (1) CN104169277B (enExample)
AU (1) AU2013218167B2 (enExample)
BR (1) BR112014019254B1 (enExample)
CA (1) CA2863759C (enExample)
DK (1) DK2812328T3 (enExample)
ES (1) ES2560260T3 (enExample)
GB (1) GB201202027D0 (enExample)
IL (1) IL233988A (enExample)
MX (1) MX338481B (enExample)
PL (1) PL2812328T3 (enExample)
PT (1) PT2812328E (enExample)
RU (1) RU2643809C2 (enExample)
SG (1) SG11201404277WA (enExample)
WO (1) WO2013117522A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2522968B2 (ja) 1987-10-23 1996-08-07 尾池工業株式会社 印刷回路転写箔およびその製造法
JP7365332B2 (ja) * 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1784386A (zh) * 2003-05-08 2006-06-07 安斯泰来制药有限公司 用作cox抑制剂的1,2－二芳基咪唑
WO2010055304A2 (en) * 2008-11-13 2010-05-20 Sareum Limited Pharmaceutical compounds
CN101796038A (zh) * 2007-05-10 2010-08-04 萨勒姆有限公司 *唑酪氨酸激酶抑制剂

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
JPH06310767A (ja) 1993-04-26 1994-11-04 Nec Corp 寒剤容器の断熱支持構造
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
BR0111754A (pt) 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
AU2479702A (en) 2000-10-30 2002-05-15 Janssen Pharmaceutica Nv Tripeptidyl peptidase inhibitors
US7361665B2 (en) 2002-07-09 2008-04-22 Vertex Pharmaceuticals Incorporated Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
ATE465731T1 (de) 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
KR101792651B1 (ko) * 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
CA2623327A1 (en) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
WO2007131953A1 (en) 2006-05-12 2007-11-22 Ab Science A new process for the synthesis of 2-aminoxazole compounds
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2320293A1 (en) * 2009-11-05 2011-05-11 Koninklijke Philips Electronics N.V. Sleep element for improving the sleep of a person
CN102812022B (zh) * 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
ES2566205T3 (es) 2012-03-02 2016-04-11 Sareum Limited Inhibidores de quinasa TYK2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1784386A (zh) * 2003-05-08 2006-06-07 安斯泰来制药有限公司 用作cox抑制剂的1,2－二芳基咪唑
CN101796038A (zh) * 2007-05-10 2010-08-04 萨勒姆有限公司 *唑酪氨酸激酶抑制剂
WO2010055304A2 (en) * 2008-11-13 2010-05-20 Sareum Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
MX338481B (es) 2016-04-19
SG11201404277WA (en) 2014-08-28
DK2812328T3 (en) 2016-01-11
BR112014019254A8 (pt) 2017-07-11
IL233988A (en) 2017-06-29
RU2014131784A (ru) 2016-03-27
CN104169277A (zh) 2014-11-26
GB201202027D0 (en) 2012-03-21
PL2812328T3 (pl) 2016-04-29
JP2015511228A (ja) 2015-04-16
RU2643809C2 (ru) 2018-02-06
AU2013218167B2 (en) 2017-04-06
BR112014019254B1 (pt) 2020-03-10
US20150018367A1 (en) 2015-01-15
US9133180B2 (en) 2015-09-15
CA2863759C (en) 2020-04-14
WO2013117522A1 (en) 2013-08-15
CA2863759A1 (en) 2013-08-15
EP2812328A1 (en) 2014-12-17
JP6034880B2 (ja) 2016-11-30
PT2812328E (pt) 2016-03-01
HK1204327A1 (en) 2015-11-13
BR112014019254A2 (enExample) 2017-06-20
KR20140128373A (ko) 2014-11-05
AU2013218167A1 (en) 2014-08-14
MX2014009323A (es) 2015-04-08
ES2560260T3 (es) 2016-02-18
EP2812328B1 (en) 2015-11-18
KR102052780B1 (ko) 2019-12-05

Similar Documents

Publication Publication Date Title
CN109776445B (zh) 苯并噁二唑类化合物及其制备方法和医药用途
JP2022508055A (ja) サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
WO2019143730A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2020135442A1 (zh) 一种fak抑制剂及其联合用药物
CN103153980B (zh) 吡唑并苯基苯磺酰胺化合物的衍生物及其作为抗肿瘤药的用途
CN108026102A (zh) 可用于治疗与kit和pdgfr相关的病症的化合物
CN110036007A (zh) 吡啶化合物
CN111372926A (zh) Wdr5蛋白质-蛋白质结合的抑制剂
CN111362967A (zh) 苯并氧杂二氮杂十四碳烯衍生物及其用途
TW202045495A (zh) １－（１－側氧基－１，２－二氫異喹啉－５－基）－５－（三氟甲基）－ｎ－（２－（三氟甲基）吡啶－４－基）－１ｈ－吡唑－４－甲醯胺一水合物的結晶形式
CN112312901B (zh) Ras癌蛋白抑制剂及其制备方法和使用方法
JP5924453B2 (ja) 二環式含窒素芳香族ヘテロ環アミド化合物
CN104169277A (zh) 极光激酶和flt3激酶调节剂
WO2023036252A1 (zh) 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
WO2019157959A1 (zh) 一种嘧啶类化合物、其制备方法及其医药用途
HK1204327B (en) Aurora and flt3 kinases modulators
WO2014000686A1 (zh) 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用
CN103626761A (zh) 苯并吡啶氮杂卓类化合物及其作为抗肿瘤药物的应用
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
HK40110795A (en) Fused ring compounds
HK40110213A (en) Fused ring compounds
HK40041215B (en) Fused ring compounds
HK40042165A (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
HK40042165B (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20161012